Dr Amarnath Challapalli

Dr Amarnath Challapalli is a Consultant Clinical Oncologist at the Bristol Cancer Institute, University Hospitals Bristol and Weston NHS Foundation Trust. He specialises in the management of urological cancers and non-melanoma skin cancers with radiotherapy, chemotherapy and immunotherapy. He undertook his medical and postgraduate training in clinical oncology in India and in the UK, achieving Fellowship of the Royal College of Radiologists. He subsequently completed a PhD at Imperial College, London in January 2014. His research focused on the translation of novel PET tracers looking at cell proliferation, apoptosis and choline metabolism into clinical studies to look at early response assessment to treatment.  Dr. Challapalli is the lead oncologist at the Bristol Cancer Institute and is a Prostate Cancer UK (PCUK) Clinical Champion. He has set up the Lutetium PSMA Radio ligand service in Bristol. He is a panel member of Mirrors in Medicine, an International Case-based professional development platform. He organises and lectures in the skin cancer study day and has co-developed the skin cancer e-learning module for the Royal College of Radiologists. He has developed and leads the brachytherapy service for non-melanoma skin cancers at the Bristol Cancer Institute. He is a member of the GEC-ESTRO HNS brachytherapy group. Dr. Challapalli is actively involved in research into urological and non-melanoma skin cancers. He is the UK Chief Investigator for the adjuvant Cemiplimab trial in high risk squamous cell carcinoma (C-POST trial), REACT-Cemi trial and a Co-Chief Investigator of the national multicentre ACE trial in prostate cancer and EPIC trial in penile cancer. His work has been published in peer-reviewed journals and presented at national and international meetings.

Genitourinary Cancers (Prostate, Bladder, Kidney, Penile and testicular cancers), Skin Cancers (Non-melanomatous cancers), Benign disease (Dupuytrens disease, Ledderhose disease, Keloid scarring)